Business Overview: Prothena Corporation plc (NASDAQ: PRTA)

---

Executive Summary

Prothena Corporation plc is an Irish-domiciled, late-stage clinical biotechnology company focused on diseases caused by protein dysregulation — primarily neurodegenerative diseases (Parkinson's, Alzheimer's, ALS) and rare peripheral amyloid diseases. The company is headquartered in Dublin, Ireland, with U.S. operations in San Francisco, and files a domestic Form 10-K with the SEC rather than a 20-F.

Prothena's distinguishing feature is a "barbell" strategy: it partners its most capital-intensive, late-stage clinical programs with large pharmaceutical companies — Roche, Novo Nordisk, and Bristol Myers Squibb (BMS) — in exchange for upfront payments, milestones, and future royalties, while funding smaller, wholly-owned early-stage research internally. FY2025 was a transition year: the company discontinued its lead wholly-owned program, birtamimab, after a Phase 3 miss, and cut its workforce by 63%, while its partnered pipeline advanced into pivotal Phase 3 trials.

---

1. Core Business Model & How They Work

Unlike a commercial-stage pharmaceutical company, Prothena does not yet generate revenue from product sales. Its economics run through partnership milestones and future royalties.

[ Internal Discovery (CYTOPE® platform) ] ➡️ [ Early-Stage / Wholly-Owned Programs ] ➡️ [ Partner Out Late-Stage, Capital-Intensive Programs (Roche / Novo Nordisk / BMS) ] ➡️ [ Upfront + Milestone Payments ] ➡️ [ Future Royalties if Approved ]

Key Operational Drivers

1. Partnership-funded late-stage development: Prothena's most advanced assets are now owned or licensed by larger partners who bear the cost of pivotal trials — prasinezumab (Parkinson's, Roche, Phase 3 PARAISO trial begun Q4 2025, ~$135M of up to $755M in milestones earned to date) and coramitug (ATTR-CM, sold to Novo Nordisk, Phase 3 CLEOPATTRA trial begun Q4 2025, ~$100M of up to $1.23B earned to date).
2. BMS collaborations on neurodegeneration: BMS-986446 (anti-tau, Alzheimer's, Phase 2 fully enrolled, up to $563M in milestones) and PRX019 (Phase 1, up to $617.5M in milestones) extend the partnered-pipeline model into Alzheimer's.
3. Wholly-owned early pipeline: PRX012/PRX012-TfR (Alzheimer's), PRX123 (Alzheimer's vaccine candidate, FDA Fast Track), and TDP-43 CYTOPE (ALS, preclinical) remain fully owned, preserving long-term upside if Prothena chooses to retain or later partner them.
4. Capital discipline after a clinical setback: after birtamimab's Phase 3 (AFFIRM-AL) failed its primary and secondary endpoints in 2025, management discontinued the program and cut headcount by 63% — a direct response that lowered the projected annualized cash burn by roughly $96 million.

---

2. Pipeline Overview

---

3. Competitive Landscape

Prothena competes against companies with far greater financial, clinical, and commercial resources across every disease area it touches:

• Parkinson's/neurodegeneration broadly: large pharma neuroscience programs at Biogen, Eli Lilly, AbbVie, and Roche's own internal pipeline (alongside its Prothena partnership) all compete for the same patient populations and investor attention.
• Alzheimer's (anti-amyloid/anti-tau): Eli Lilly (donanemab) and Biogen/Eisai (lecanemab) have already achieved approved, marketed anti-amyloid antibodies, setting a high commercial and clinical bar that Prothena's and BMS's later-stage anti-tau approach must still clear.
• Amyloid/rare disease: smaller specialized biotechs (e.g., Alnylam, Ionis/Akcea in transthyretin amyloidosis) compete directly in the ATTR space where coramitug is headed, alongside already-approved therapies (e.g., tafamidis).
• Positioning: Prothena does not attempt to compete commercially at all today — its strategy is to let larger, better-resourced partners run the expensive late-stage trials and commercialization, while Prothena captures economics through milestones and royalties rather than bearing full launch risk itself.

---

4. Strategic Strengths & Risks

Strengths (The Moat)

• CYTOPE® discovery platform: a proprietary antibody-discovery technology targeting toxic, misfolded protein conformations — the scientific engine behind both the partnered and wholly-owned pipeline, and the basis for three separate big-pharma partnerships.
• Multiple, independently-validated big-pharma partnerships: having Roche, Novo Nordisk, and BMS each independently commit hundreds of millions of dollars in milestone potential to Prothena-originated science is a strong external validation of the platform's quality that a smaller or newer biotech could not easily obtain.
• Debt-free balance sheet: $308.4 million in cash, cash equivalents, and restricted cash at year-end 2025 with no debt, giving the company genuine optionality without near-term refinancing risk.

Risks

• No near-term product revenue: FY2025 total revenue was just $9.7 million (almost entirely a BMS collaboration milestone), down from $135.2 million in 2024 — revenue is lumpy, milestone-driven, and not yet a recurring royalty stream, since no partnered or owned program has reached commercial approval.
• Binary late-stage clinical risk: the pivotal PARAISO and CLEOPATTRA Phase 3 trials are not expected to read out primary completion until 2029, a long runway over which a single trial failure (as happened with birtamimab in 2025) can erase years of value.
• Dependence on partner decisions: BMS's 2026 decision on whether to continue developing PRX019, and Roche's/Novo Nordisk's continued prioritization of their respective programs, are largely outside Prothena's control yet materially affect its future economics.
• Continued net losses: FY2025 net loss was $244.1 million (including $30.1 million of restructuring charges); FY2026 guidance still calls for an estimated $67–72 million net loss and $50–55 million of net cash used, meaning the company continues to burn cash absent new milestones.

---

5. Financial Overview

---

6. Summary Conclusion

Prothena's moat is almost entirely about the quality and validation of its underlying science — a proprietary antibody-discovery platform that has drawn three separate, large, independently-committed pharmaceutical partners — rather than any commercial moat, since it has no marketed products and therefore no pricing power, cost advantage, or switching costs to speak of today. The company enters 2026 financially stable (debt-free, ~$300M cash, no going-concern issue) after decisively cutting costs following birtamimab's Phase 3 failure, but its path to real equity value creation now runs through two long-dated, binary Phase 3 readouts (prasinezumab and coramitug, both targeting 2029 primary completion) that it does not fully control.